Physician profile
Andrew J Scripture
NPI 1043716079
$9,301.55
in general payments reported to CMS, 2019-2025
30 companies · $3,273 in 2025
The $3,273 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $762 · 2023: $2,450 · 2024: $2,817 · 2025: $3,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,954 · Education: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,954.07 |
| Education | $585.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,838.64 | 2022-2025 | Absorica Ld, Winlevi, Ilumya |
| Abbvie INC. | $1,154.24 | 2022-2025 | |
| Janssen Biotech, INC. | $1,012.97 | 2022-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $713.63 | 2022-2025 | Dupixent, Libtayo |
| Amgen INC. | $708.33 | 2022-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $567.23 | 2022-2025 | |
| Genzyme Corporation | $563.60 | 2022-2025 | |
| Galderma Laboratories, L.P. | $450.24 | 2023-2025 | Nemluvio, Epsolay, Oracea |
| Pfizer INC. | $368.66 | 2022-2025 | |
| Lilly USA, LLC | $352.33 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $341.47 | 2022-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $197.98 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $191.92 | 2023-2024 | Vtama |
| Biofrontera INC. | $161.46 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Verrica Pharmaceuticals INC. | $78.57 | 2023-2025 | Ycanth |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $72.68 | 2023-2025 | Opzelura |
| Ucb, INC. | $72.14 | 2024-2025 | Bimzelx |
| Journey Medical Corporation | $66.55 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $61.13 | 2024-2025 | Cabtreo, Siliq |
| Almirall LLC | $52.60 | 2022-2025 | Klisyri |
| Paratek Pharmaceuticals, INC. | $47.73 | 2022-2023 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.34 | 2023-2024 | Spevigo |
| Arcutis Biotherapeutics, INC. | $35.97 | 2024-2025 | Zoryve |
| Botanix Sb INC | $35.53 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $35.19 | 2022-2023 | |
| Celgene Corporation | $22.03 | 2024 | Sotyktu |
| Organogenesis INC. | $20.24 | 2024 | |
| Strata Skin Sciences, INC. | $15.46 | 2025 | Xtrac |
| Smith+Nephew, INC. | $13.27 | 2024 | Collagenase Santyl |
| Organon LLC | $3.42 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Scripture listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.